<DOC>
	<DOCNO>NCT02497027</DOCNO>
	<brief_summary>This randomize , control group design pharmacogenetic implementation mental health population subject take anti-depressants and/or anti-psychotics new current primary secondary diagnosis Major Depressive Disorder ( MDD ) Depressive Disorder Not Otherwise Specified ( DDNOS ) .</brief_summary>
	<brief_title>Pharmacogenetic Testing Outpatient Population Patients With Depression</brief_title>
	<detailed_description>This randomize , control group design pharmacogenetic implementation mental health population subject take anti-depressants and/or anti-psychotics new current primary secondary diagnosis Major Depressive Disorder ( MDD ) Depressive Disorder Not Otherwise Specified ( DDNOS ) . Prospective data collect subject study completion 24-25 week post enrollment . Claims data may review per pay , data readily available timely manner .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<criteria>Current primary secondary diagnosis Major Depressive Disorder Depressive Disorder Not Otherwise Specified Have moderate severe depression identify PHQ9 score 10 great Taking newly prescribe antidepressant antipsychotic medication Able provide inform consent Prescribing physician practice Avera Medical Group University Psychiatry Associates clinic Sioux Falls , SD Pregnant breastfeed Active and/or unstable diagnosis substance abuse , exclude nicotine Primary diagnosis dementia , bipolar disorder ( type ) , schizophrenia , schizoaffective disorder , personality disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>pharmacogenetic , pharmacogenomic , depressive , mental health</keyword>
</DOC>